BLA 761128 · Novartis Pharms Corp
Adakveo
Crizanlizumab-Tmca · Injection · Selectin Blocker
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jun 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Nov 15, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
14
2 Phase 3, 3 recruiting
FAERS reports
1,397
759 serious, 55 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 4, 2026.
ADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. ADAKVEO is a selectin blocker indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.
Mechanism: Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands, including P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab can also dissociate preformed P-selectin/PSGL-1 complex. Binding P-selectin on the surface of the activated endothelium and platelets blocks interactions between endothelial cells, platelets, red blood cells, and leukocytes.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 26, 2024 Supplement 6 · Efficacy OrphanLetterLabel
- Nov 15, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- ADAKVEO · CRIZANLIZUMAB-TMCA 100MG/10ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Crizanlizumab" as an intervention, any sponsor and status, largest first.
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTEPivotal-lookingCompleted
Matthew Neal MDAcademic, hospital or other
NCT04505774 · 3,591 participants · Start Sep 4, 2020 · Primary completion Aug 31, 2023
Drug: theraputic heparin; prophylactic heparin and 3 more · For: Covid19
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 101 sites in all
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06439082 · 354 participants (planned) · Start Oct 24, 2024 · Primary completion Jul 2, 2029
Drug: Crizanlizumab; Placebo · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Orange, California; Washington D.C., District of Columbia · 36 sites in all
- Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease PatientsPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03814746 · 253 participants · Start Jul 26, 2019 · Primary completion Aug 31, 2022
Drug: Crizanlizumab (SEG101); Placebo · For: Sickle Cell Disease (SCD)
Sites: Atlanta, Georgia; Boston, Massachusetts; Charlotte, North Carolina · 58 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04662931 · 140 participants · Start Jul 14, 2021 · Primary completion Feb 14, 2024
Drug: crizanlizumab · For: Sickle Cell Disease (SCD)
Sites: Guwahati, India; Raipur, India; Kozhikode, India · 7 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04657822 · 130 participants (planned) · Start Jun 10, 2021 · Primary completion Jun 10, 2031
Drug: Crizanlizumab · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Washington D.C., District of Columbia; Augusta, Georgia · 31 sites in all
- Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease PatientsCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03474965 · 117 participants · Start Oct 1, 2018 · Primary completion Nov 6, 2024
Drug: Crizanlizumab · For: Sickle Cell Disease (SCD)
Sites: Birmingham, Alabama; Washington D.C., District of Columbia; Gainesville, Florida · 35 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04053764 · 58 participants · Start Dec 10, 2019 · Primary completion Mar 20, 2023
Drug: Crizanlizuamb; Standard of Care · For: Sickle Cell Disease (SCD)
Sites: Birmingham, Alabama; Chicago, Illinois; Baton Rouge, Louisiana · 24 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT03264989 · 57 participants · Start Dec 19, 2017 · Primary completion Jun 26, 2023
Drug: crizanlizumab · For: Sickle Cell Disease (SCD)
Sites: Orange, Florida; Tampa, Florida; Atlanta, Georgia · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- sickle cell anaemia with crisis364
- pain353
- back pain151
- infusion related reaction131
- arthralgia95
- pain in extremity89
- chest pain81
- nausea80
- drug ineffective79
- pyrexia76
- headache71
- fatigue68
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 4 |
| 2020 | 343 |
| 2021 | 426 |
| 2022 | 331 |
| 2023 | 114 |
| 2024 | 113 |
| 2025 | 45 |
| 2026 | 21 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Adakveo (Crizanlizumab-Tmca)
2024 spending
$5.0M
Beneficiaries
85
476 claims
Per beneficiary
$58,308
$240.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,098,451 |
| 2021 | $5,852,210 |
| 2022 | $6,859,658 |
| 2023 | $6,747,857 |
| 2024 | $4,956,211 |
Part B: Adakveo (Crizanlizumab-Tmca) · HCPCS J0791
2024 spending
$26.0M
Beneficiaries
419
2,703 claims
Per beneficiary
$62,060
2024 ASP limit $127.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $13,054,000 |
| 2021 | $31,071,224 |
| 2022 | $31,259,411 |
| 2023 | $29,665,792 |
| 2024 | $26,003,300 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI, Kutlar A, Kanter J, et al. · N Engl J Med 2017 · Clinical Trial, Phase II, Multicenter Study
- Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study.
Wang WX, Spiegelman D, Rao PK, et al. · J Clin Invest 2024 · Clinical Trial, Phase II, Multicenter Study
- Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial.
Abboud MR, Cançado RD, De Montalembert M, et al. · Lancet Haematol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Crizanlizumab in vaso-occlusive crisis caused by sickle cell disease.
Gardner RV · Drugs Today (Barc) 2020 · Clinical Trial
- Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.
Thom H, Jansen J, Shafrin J, et al. · BMJ Open 2020 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
Han J, Saraf SL, Gordeuk VR · Pharmacotherapy 2020 · Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.